POC(Point of Care)에서의 주사제 재구성

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

자가투여용으로 개발된 약제가 증가하면서 재구성 단계와 주사 단계를 통합한 기기가 인기를 얻고 있습니다. 생물학적 제제가 치료법이나 처방 건수 면에서 성장을 지속함에 따라 특수한 기기의 영향이 높아지고 있습니다.

POC(Point of Care)에서의 주사제 재구성에 대해 조사했으며, 시장 역학, 시장 요인, 성장요인, 디바이스 제품 전략, 기업 프로파일 등의 정보를 전해드립니다.

목차

• 개요
• POC에서의 주사제 재구성
• 의약품 재구성 시장 역학
• 재구성 - 생물학적 제제 수명의 사실
• 주사제 에코시스템
• 디바이스 설계의 진화
• 제제 요인
• 제품 고유의 디바이스 개발
• 특수 주입 장치의 수요 촉진요인
• 만성질환과 자가투여
• 생물학적 제제의 성장
• 처방과 투약
• 환자층의 변화
• 안전 및 준수
• 디바이스 설계와 혁신
• 경쟁 구도
• 기술 시장 촉진요인
• POC 재구성을 위한 통합 디바이스
• 듀얼 챔버 카트리지
• 듀얼 챔버 인젝터
• 듀얼 챔버 주사기
• 웨어러블 자동 탐지 시스템
• 디바이스 평가
• 제품 고유의 디바이스
• 특수 디바이스
• OEM 디바이스
• 듀얼 챔버 안전 주사기(Credence)
• 치료 부문 - 데이터와 예측
• 호르몬 보충
• 감염증
• 대사질환
• 골다공증
• 신경학
• 종양학
• 생식건강
• 기타 치료 부문
• 시장 요인
• 디바이스 제품 전략
• 디바이스 경제학
• 제품 브랜딩
• 직접 판매 마케팅
• 매니지드 케어 동향
• 기업 개요

Engineered Injectables that Address Chronic Conditions

The inherent instability of biological drugs is a limitation that has a direct impact on the drug delivery sector. Therapeutic proteins must either be stored under special conditions or formulated to retain their efficacy from the time of manufacture until they are dispensed. Liquid protein drugs require refrigeration until dispensed. Alternatively, proteins can be formulated as powders (lyophilization) and must be reconstituted prior to injection. Historically, this was accomplished by including a disposable syringe and diluent vial for manual reconstitution. As the number of drugs developed for self-administration has grown, devices that integrate a reconstitution step with the injection step have gained traction. As biological drugs continue to grow in terms of therapeutics and total prescriptions, the impact of specialty devices will increase.

What You Will Learn:

• What is the impact of lyophilized injectable drugs on today's therapeutic market, how are they packaged, and who markets them?

• Who are the suppliers of integrated reconstitution devices, and what is their market impact?

• What are the major factors driving the demand for integrated devices for injectable drug reconstitution?

• What is the relative impact of integrated reconstitution systems to OEM or standalone reconstitution devices and how will this change by the end of the decade?

• What are the essential design factors, material selection issues, technologies and market development issues for drug reconstitution systems and devices?

• What is the role of integrated drug reconstitution systems on drug life cycle management?

• What are the significant economic, technology, and regulatory factors affecting the market for injectable drugs and reconstitution systems in particular?

Table of Contents

• Executive Summary
• Reconstituting Injectables at the PoC
• Drug Reconstitution Market Dynamics
• Reconstitution - A Fact of Biological Drug Life
• The Injectable Drug Ecosystem
• Evolution in Device Design
• Formulation Factors
• Product Specific Device Development
• Specialty Injection Device Demand Drivers
• Chronic Conditions and Self-Administration
• The Growth of Biologicals
• Formulation and Dosing
• Shifting Patient Demographics
• Safety and Adherence
• Device Design and Innovation
• Competitive Landscape
• Technology Market Drivers
• Integrated Devices for POC Reconstitution
• Dual Chamber Cartridges
• Dual Chamber Injectors
• Dual Chamber Syringes
• Wearable Automated Recon System
• Device Assessments
• Product-Specific Devices
• Specialty Devices
• OEM Devices
• Dual Chamber Safety Syringe (Credence
• Therapeutic Segments - Data & Forecasts
• Hormone Replacement
• Infectious Disease
• Metabolic Conditions
• Osteoporosis
• Neurology
• Oncology
• Reproductive Health
• Other Therapeutic Segments
• Market Factors
• Device Product Strategies
• Device Economics
• Product Branding
• Direct-to-Consumer Marketing
• Managed Care Trends
• Company Profiles